Use of a super active luteinizing hormone releasing hormone (LHRH) agonist in the treatment of menorrhagia

Summary. A luteinizing hormone releasing hormone agonist, d-Ser(But)⁶des Gly¹⁰-LHRH ethylamide, was administered intranasally to four women with unexplained ovulatory menorrhagia. Dramatic reductions in excessive menstrual blood losses were induced without significant side-effects, although the pattern of loss returned to pretreatment levels within 2 months of ceasing therapy.